InvestorsHub Logo
Followers 971
Posts 383037
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Thursday, 10/26/2023 7:47:17 AM

Thursday, October 26, 2023 7:47:17 AM

Post# of 118379
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.

$RGBP
Bullish
Bullish